Massive study aims to decode lung disease progression
NCT ID NCT07178392
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will observe 2,864 people with idiopathic pulmonary fibrosis (IPF) to learn how the disease changes over time and how it relates to traditional Chinese medicine syndromes. Researchers will track lung function, exercise ability, quality of life, and other health markers. The goal is to better understand IPF at different stages, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand how IPF progresses and improve how they classify and treat the disease.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,864 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Idiopathic pulmonary fibrosis (IPF) is a special type of idiopathic interstitial pneumonia, which is mainly manifested by irritating dry cough and progressive dyspnea.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients diagnosed with IPF; 2. Age ≥ 18 years old; 3. Voluntarily participate in this study and sign an informed consent form. Exclusion Criteria: 1. Patients with confusion, dementia, consciousness disorders, and various mental illnesses; 2. Those who are unable to take care of themselves and have been bedridden for a long time.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis (IPF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou, Henan, 450000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can a new daily pill slow lung scarring in IPF?
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays